Vericel to Report Second-Quarter 2024 Financial Results on August 1, 2024
18 Juillet 2024 - 2:30PM
Vericel Corporation (NASDAQ:VCEL), a leader in advanced therapies
for the sports medicine and severe burn care markets, today
announced that it will report its second-quarter 2024 financial
results on Thursday, August 1, 2024. Vericel’s management will host
a conference call and webcast at 8:30 a.m. (ET) to discuss its
financial results and business highlights.
The live webcast can be accessed on the Investor Relations
section of the Vericel website at
http://investors.vcel.com/events-presentations. Please visit the
site at least 15 minutes prior to the scheduled start time in order
to register and download the required audio software, if necessary.
Presentation slides for the conference call will be available on
the webcast and on the Investor Relations section of the Vericel
website.
To participate by telephone, please register here to receive
dial-in details and your personal passcode. A replay of the webcast
will be available on the Vericel website until August 1, 2025.
About Vericel Corporation
Vericel is a leading provider of advanced therapies for the
sports medicine and severe burn care markets. The Company combines
innovations in biology with medical technologies, resulting in a
highly differentiated portfolio of innovative cell therapies and
specialty biologics that repair injuries and restore lives. Vericel
markets three products in the United States. MACI® (autologous
cultured chondrocytes on porcine collagen membrane) is an
autologous cellularized scaffold product indicated for the repair
of symptomatic, single or multiple full-thickness cartilage defects
of the knee with or without bone involvement in adults. Epicel®
(cultured epidermal autografts) is a permanent skin replacement for
the treatment of patients with deep dermal or full thickness burns
greater than or equal to 30% of total body surface area. Vericel
also holds an exclusive license for North American rights to
NexoBrid® (anacaulase-bcdb), a biological orphan product containing
proteolytic enzymes, which is indicated for the removal of eschar
in adults with deep partial-thickness and/or full-thickness burns.
For more information, please visit www.vcel.com.
Epicel and MACI are registered trademarks of Vericel
Corporation. NexoBrid is a registered trademark of MediWound Ltd.
and is used under license to Vericel Corporation. © 2024 Vericel
Corporation. All rights reserved.
Investor Contact:Eric Burnsir@vcel.com+1 (734)
418-4411
Media Contact:Julie Downsmedia@vcel.com
Vericel (NASDAQ:VCEL)
Graphique Historique de l'Action
De Juil 2024 à Août 2024
Vericel (NASDAQ:VCEL)
Graphique Historique de l'Action
De Août 2023 à Août 2024